Pregabalin

Anticonvulsant

Also sold as Lyrica.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Pregabalin's own pharmacokinetics rule out most of the classical machinery that drives drug-nutrient interactions. It is not appreciably metabolized (about 90% of an oral dose is recovered unchanged in urine), does not induce or inhibit any of the seven CYP450 isoforms tested against it in vitro, does not bind plasma proteins, and is cleared renally as intact drug with a roughly 6-hour half-life. There is no enzyme induction, no CYP inhibition, and, unlike gabapentin, no aluminum-hydroxide or magnesium-hydroxide antacid interaction documented anywhere in pregabalin's own FDA label. On mechanism alone, pregabalin starts this review with almost no classical pathway for causing a nutrient deficiency.

ATC N03AX16 · also sold as Lyrica · reviewed 2026-09-06, expanded September 10, 2026. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Pregabalin in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe: severe: 2+ independent Tier A sources, this drug in the studied cohort, direct measurement, consistent direction and clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate: moderate: 1+ Tier A source with this drug in the cohort showing a real but bounded deficit (exposure window, definable subgroup, or association without a retrievable effect size).
Yellow — Low: low or theoretical: mechanistic plausibility only, class-level extrapolation without drug-specific human data, or a context flag such as a confirmed reverse-direction interaction or an indication-linked baseline prevalence.
Not graded — disclosed evidence gap: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: no color, non-tier: used only when no Tier B mechanistic or Tier C class-extrapolation evidence exists to support even yellow, and no circulating consumer claim exists to rebut as white. A genuine evidence gap, printed as a gap, never converted into reassurance.

What the research found

Vitamin B12

Orange — Moderate

See study details

One large epilepsy-cohort study named pregabalin, specifically, among the drugs associated with lower vitamin B12 levels, not folate, but without a reported pregabalin-only effect size.

Full detail, limits and 1 references

What the grade means here: moderate: 1+ Tier A source with this drug in the cohort showing a real but bounded deficit (exposure window, definable subgroup, or association without a retrievable effect size). Orange · moderate

Limits on what this shows

Key negative / null findings: In the same cohort, pregabalin was not among the drugs associated with lower folate (that group was carbamazepine, gabapentin, oxcarbazepine, phenytoin, primidone, and valproate) — a distinction the primary abstract draws explicitly. Valproate showed higher B12 than the group average in the same study, underscoring that this is a drug-specific pattern, not a uniform class effect.
At-risk subgroups: Patients with epilepsy taking pregabalin, particularly alongside other AEDs, matching the population this study actually sampled. Not established for pregabalin's pain or fibromyalgia populations, which this cohort did not include.

Regulatory status

Not addressed in the FDA label. No monitoring requirement or nutrient warning appears anywhere in pregabalin's prescribing information.

Population evidence

Linnebank et al., Ann Neurol 2011;69(2):352–359. Prospective, single-center, cross-sectional cohort at University Hospital Bonn: 2,730 AED-treated patients with epilepsy, 170 untreated patients with epilepsy, and 200 healthy controls. Verbatim result: "Treatment with phenobarbital, pregabalin, primidone, or topiramate was associated with lower vitamin B12 levels compared with the entire group of patients." No pregabalin-only sample size, percentage, odds ratio, or confidence interval appears in the abstract, and the publisher's full text could not be opened after repeated attempts, so a per-drug table could not be independently checked.

Mechanism

None established specifically for pregabalin. It has no CYP induction and no confirmed absorption-chelation pathway, so the route connecting pregabalin to lower B12 in this cohort is not identified; epilepsy-specific dietary factors and co-administered enzyme-inducing AEDs are plausible, uncontrolled alternative explanations.

Counter-evidence held on record

A cross-sectional, single-center design cannot establish causation or timing. Confounding by indication is not excluded: epilepsy itself, diet, and co-medication all plausibly affect B12 independent of pregabalin. No dose-response or replication cohort specific to pregabalin was located. A consumer drug-interaction checker (Drugs.com) lists no known pregabalin–B12 interaction, indicating this association has not entered routine clinical interaction screening. Present this as an observational signal from one epilepsy-focused cohort study, not a quantified or confirmed deficiency risk. Do not state a percentage, incidence, or "depletes" framing that the source does not support, and do not extend this finding to pregabalin's non-epilepsy populations, which this study never sampled.

Mintzer S, Skidmore CT, et al. "B-vitamin deficiency in patients treated with antiepileptic drugs." — Epilepsy Behav. 2012. Secondary review citing Linnebank et al. 2011; groups pregabalin with gabapentin and valproate as "non-inducing" AEDs among which deficiency was more common, without a separate pregabalin effect size. Used only for corroborating context, not as a primary numeric source. PMID 22658435.

Food slows absorption rate

Yellow — Low

See study details

Food delays and blunts pregabalin's peak concentration, but this is food acting on the drug, not the drug depleting a nutrient, and pregabalin's label carries none of gabapentin's antacid-specific bioavailability warning.

Full detail and limits

What the grade means here: low or theoretical: mechanistic plausibility only, class-level extrapolation without drug-specific human data, or a context flag such as a confirmed reverse-direction interaction or an indication-linked baseline prevalence. Yellow · context

Limits on what this shows

Key negative / null findings: Extent of absorption (AUC) is unchanged by food. No clinically meaningful interaction with calcium, magnesium, or iron supplements specifically is described anywhere in the label.
At-risk subgroups: None specific. Patients taking pregabalin with meals may see a delayed onset of effect; this is a pharmacokinetic timing note, not a nutrient-status issue.

Regulatory status

FDA label states food decreases Cmax by roughly 25–30% and delays Tmax to about 3 hours, with AUC (total absorption) unaffected; no dosage adjustment for meal timing is recommended.

Population evidence

Single- and multiple-dose pharmacokinetic studies referenced in the label's clinical pharmacology section. No separate published human cohort beyond the label's own data was located.

Mechanism

Mechanism class F (GI absorption/transit-time-mediated rate change), not gut chelation. No aluminum-hydroxide or magnesium-hydroxide antacid interaction is described in the label, a verified, genuine difference from gabapentin's own label, which does carry that specific mineral-antacid warning.

Counter-evidence held on record

No study was found showing a clinically meaningful pregabalin efficacy loss from meal timing; the label recommends no dose or timing adjustment. This is a drug-timing note, not a nutrient finding, and must never be worded as "pregabalin depletes X" or paired with a mineral-supplement separation instruction the label does not support.

Vitamin D

Yellow — Low

See study details

Fibromyalgia and chronic neuropathic pain, two of pregabalin's main indications, carry their own well-documented baseline association with low vitamin D status, a confound to separate from any claim about the drug itself.

Full detail and limits

Limits on what this shows

Key negative / null findings: A prospective Wistar rat study dosing both gabapentin and pregabalin found no significant change in bone mineral density or biomechanical strength for either drug. A human primary-osteoblast and mesenchymal-stem-cell study found pregabalin produced an osteoanabolic (bone-forming), not depleting, effect on mineralization markers at therapeutic concentrations. Neither study measured vitamin D or phosphate directly.
At-risk subgroups: Patients with fibromyalgia or chronic pain independent of pregabalin use. Confounding by indication should be presumed until a pre/post-treatment cohort actively excludes it.

Regulatory status

Not addressed anywhere in the FDA label.

Population evidence

Vitamin D status is studied in fibromyalgia populations independent of pregabalin exposure. A 2025 systematic review and meta-analysis of vitamin D supplementation in fibromyalgia (7 studies reviewed, 4 pooled) found a significant pain reduction with supplementation (standardized mean difference −0.85, 95% CI −1.54 to −0.17). A separate 12-week randomized trial of weekly 50,000 IU vitamin D3 in 80 fibromyalgia patients found no improvement in pain (VAS) or functional impact (FIQ) scores despite a confirmed rise in vitamin D levels. The literature is mixed on whether correcting vitamin D helps fibromyalgia symptoms, but it consistently treats vitamin D status as a preexisting feature of the fibromyalgia population, not a downstream effect of any specific drug.

Mechanism

None connecting pregabalin's own pharmacology to vitamin D loss. A 2022 narrative review of gabapentinoid effects on the musculoskeletal system (combining gabapentin and pregabalin data without separating them) proposes a direct α2&delta-1 calcium-channel-subunit role in bone and muscle tissue linked to fracture risk, but does not propose or discuss a vitamin D metabolism or activation pathway anywhere in its text. An extensive targeted search could not locate any peer-reviewed source establishing a vitamin-D-activation mechanism specific to gabapentinoids.

Counter-evidence held on record

No pregabalin-specific human study measuring vitamin D or phosphate before and after treatment was located. The two available pregabalin-specific mechanistic studies (rat bone turnover, human osteoblast) argue against, rather than for, a depletion narrative. Do not present vitamin D status in pregabalin-treated patients as caused by the drug. It reflects the underlying condition (fibromyalgia, chronic pain, reduced mobility) far more than any documented pharmacology.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden

Yellow — Low

See study details

Pregabalin's calcium-channel mechanism creates a structural reason to ask whether it could disturb mitochondrial calcium buffering, but the one direct pregabalin study that tested this specific question in a live cell system found selectivity for the calcium channel and no effect on mitochondria.

Full detail, limits and 3 references

Limits on what this shows

Key negative / null findings: The chromaffin-cell study above is itself the key null finding: no mitochondrial effect detected specifically for pregabalin at the concentrations and cell system tested. A separate publication indexed under "direct mitochondrial toxicity in drug-induced rhabdomyolysis" (Bin Dayel FF, Alfirevic A, Chadwick AE. Biomedicines. 2023;PMID 37239154) appeared in this review's search results and, per an automated summarization of the source, may have flagged pregabalin among tested agents; repeated attempts to independently open and verify the primary abstract returned 429 errors during this session, so that specific claim is flagged here as unverified rather than cited as confirmed evidence, per this dossier's citation-integrity rule.
At-risk subgroups: None established. A 2019 clinical trial of coenzyme Q10 supplementation in pregabalin-treated fibromyalgia patients (Sawaddiruk P, Apaijai N, et al. Free Radical Research. 2019;PMID 31387429) discusses mitochondrial dysfunction in this population, but fibromyalgia itself carries an independent, well-documented association with mitochondrial dysfunction; this review treats that trial as confounded by indication, not as evidence that pregabalin caused the mitochondrial finding, consistent with how this dossier already treats fibromyalgia-linked vitamin D status above.

Regulatory status

Not addressed anywhere in the FDA label. No mitochondrial toxicity warning, monitoring requirement, or signal of any kind appears in pregabalin's prescribing information.

Population evidence

Hernández-Vivanco A, Pérez-Álvarez A, et al. "Selectivity of action of pregabalin on Ca(2+) channels but not on fusion pore, exocytotic machinery, or mitochondria in chromaffin cells of the adrenal gland." J Pharmacol Exp Ther. 2012;PMID 22537772. A direct pregabalin-dosed in vitro study in adrenal chromaffin cells, testing exactly this question: title and confirmed listing state pregabalin acted selectively on Ca(2+) channels without affecting mitochondria in this system. This is Tier B, drug-specific, and a null result, not a positive burden finding.

Mechanism

Mechanism class E (mitochondrial interference), theoretical only: mitochondria buffer intracellular calcium at presynaptic terminals, and pregabalin binds the α2&delta subunit that gates presynaptic calcium influx, which is the textbook reason a calcium-channel ligand could in principle affect mitochondrial calcium handling. This is general pharmacology plausibility (Tier B), not a demonstrated pregabalin effect; the one study that directly tested it found no such effect in the system studied.

Counter-evidence held on record

The direct chromaffin-cell test is itself counter-evidence to a mitochondrial-burden claim, not just an absence of support. No human pregabalin study measuring mitochondrial markers independent of the fibromyalgia confound was located. Do not present this as an established or even probable mitochondrial risk. The strongest direct evidence found argues against an effect; this entry exists to document a theoretical pathway and an evidence gap, not to imply a concern.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress

Yellow — Low

See study details

Several rat studies dosing pregabalin at high doses for long durations report tissue oxidative-stress and apoptosis markers in specific organs, while a separate pregabalin-dosed animal study reports the opposite, a neuroprotective, oxidative-stress-reducing effect; the animal literature is genuinely mixed in direction and confined to non-clinical dosing.

Full detail, limits and 4 references

Limits on what this shows

Key negative / null findings: The spinal-cord-injury study above is itself a directly contradicting finding, reporting a protective rather than damaging oxidative-stress effect for pregabalin. No human study measuring oxidative-stress markers in pregabalin-treated patients was located.
At-risk subgroups: None established in humans. The damaging-direction studies specifically describe long-term, high, non-clinical rat doses (testicular and neurotoxicity models); this is a dose-and-duration-bounded signal, not evidence at labeled human dosing.

Regulatory status

Not addressed anywhere in the FDA label. No oxidative-stress marker or monitoring requirement appears in pregabalin's prescribing information.

Population evidence

Four direct pregabalin-dosed animal studies located via PubMed search listing (titles and bibliographic details confirmed; full quantitative abstracts could not be retrieved in this review due to repeated source rate-limiting). Taha SHN, Zaghloul HS, et al. "The neurotoxic effect of long-term use of high-dose Pregabalin and the role of alpha tocopherol in amelioration: implication of MAPK signaling with oxidative stress and apoptosis." Naunyn Schmiedebergs Arch Pharmacol. 2020;PMID 32377769, and a companion paper on testicular tissue, Mol Biol Rep. 2020;PMID 33051752, both report oxidative-stress and apoptosis markers under long-term, high-dose rat dosing, by the studies' own titles. Ajayi AF, et al. "Melatonin protect against pregabalin-induced gonadotoxicity via anti-oxidative... mechanisms in rats." BMC Pharmacol Toxicol. 2025;PMID 39940050, reports a similar pregabalin-induced oxidative pattern in gonadal tissue, again ameliorated by a co-administered antioxidant, not evidence that pregabalin itself depletes that antioxidant. Directly contradicting these in direction: Güdü BO, et al. "Neuroprotective effects of pregabalin in experimental spinal cord injury: An investigation of oxidative stress and antioxidant enzymes in blood and neural tissue." Ulus Travma Acil Cerrahi Derg. 2026;PMID 41821277, whose title reports a neuroprotective, not damaging, oxidative-stress effect for pregabalin in a different animal injury model.

Mechanism

No single named mechanism unifies these findings; the titles alone report the direction (tissue oxidative damage in three high-dose, long-duration rat toxicity studies versus a protective effect in one spinal-cord-injury model), and this review could not retrieve full text to compare dosing, tissue, or duration side by side. This is Tier B, drug-specific, animal-only evidence in both directions, not a demonstrated human mechanism.

Counter-evidence held on record

A pregabalin-dosed animal study reporting a neuroprotective, oxidative-stress-reducing effect exists directly alongside the damaging-direction studies; the animal literature does not point in one consistent direction, and no clinically-dosed or human data exist to resolve it. Do not present this as a confirmed human oxidative-stress risk. The supporting studies use long-term, high, non-clinical rodent doses, a directly contradicting animal finding exists, and no human marker data exist at any dose.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Yellow — Low

Direction: reverse direction (as labelled in the source)

The only direct pregabalin-copper study located shows pregabalin antagonizing copper-induced neurotoxicity, not depleting or elevating the body's copper status; this is filed as a context flag under the reverse-direction rule, not as a deficiency or excess finding.

Full detail, limits and 1 references

Limits on what this shows

Key negative / null findings: No study located in this review measured serum copper, ceruloplasmin, or any circulating copper parameter in pregabalin-treated patients or animals. No mechanism by which pregabalin would alter copper absorption (no gut chelation, confirmed absent elsewhere in this dossier), renal handling, or hepatic storage was located.
At-risk subgroups: None established for a copper-status effect. The located study does not describe a patient population; it is an in vitro/in vivo mechanistic study of copper's own toxicity.

Regulatory status

Not addressed anywhere in the FDA label. No copper-specific interaction, monitoring requirement, or warning appears in pregabalin's prescribing information.

Population evidence

Marmolino D, Manto M. "Pregabalin antagonizes copper-induced toxicity in the brain: in vitro and in vivo studies." Neurosignals. 2010;PMID 21196706. Direct pregabalin-dosed in vitro and in vivo study; title and confirmed listing describe pregabalin blocking copper's own neurotoxic action, the opposite of a drug-depletes-nutrient or drug-elevates-nutrient claim.

Mechanism

Proposed as a pharmacodynamic interaction at the level of copper's own toxic action on neurons (plausibly via pregabalin's calcium-channel activity dampening a calcium-dependent step in copper-induced injury), not a mechanism by which pregabalin alters absorption, excretion, or serum status of copper itself. Per this dossier's mandatory direction check, a drug blocking a nutrient's toxic action on a target tissue is not the same as a drug affecting the nutrient's own physiological status, and is not graded as a depletion or excess finding.

Counter-evidence held on record

No evidence of any kind, at any tier, supports a claim that pregabalin depletes or elevates copper status. The one relevant study runs in a direction that would, if anything, argue against a copper-toxicity narrative involving pregabalin. Never present this as a copper deficiency or excess risk. The only real pregabalin-copper literature found describes the drug blocking copper's neurotoxic action, not altering the body's copper status in either direction, and no supplement or monitoring implication follows from it.

Marmolino D, Manto M. "Pregabalin antagonizes copper-induced toxicity in the brain: in vitro and in vivo studies." — Neurosignals. 2010. PMID 21196706. Direct pregabalin-dosed in vitro and in vivo study; describes pregabalin blocking copper's own neurotoxic action, not a drug-affects-copper-status finding.

Iron

Yellow — Low

See study details

Restless legs syndrome, one of pregabalin's treatment contexts, carries a well-established, independent association with low brain and body iron status; no study located in this review measured a pregabalin-attributable change in iron or ferritin, and confounding by indication is presumed to apply here exactly as it does for vitamin D and fibromyalgia above.

Full detail, limits and 1 references

Limits on what this shows

Key negative / null findings: No pregabalin-specific human study measuring serum iron, ferritin, or transferrin saturation before and after treatment was located in this review.
At-risk subgroups: Patients with restless legs syndrome independent of pregabalin use. Confounding by indication should be presumed until a pre/post-treatment cohort actively excludes it, which this review did not find.

Regulatory status

Not addressed anywhere in the FDA label. No iron-specific interaction, monitoring requirement, or warning appears in pregabalin's prescribing information.

Population evidence

Iron status in restless legs syndrome is studied extensively independent of pregabalin exposure. Trenkwalder C, Allen R, Högl B, et al. "Comorbidities, treatment, and pathophysiology in restless legs syndrome." Lancet Neurol. 2018;PMID 30244828, a class-level review, discusses both iron-repletion therapy and pregabalin as separate treatment approaches for restless legs syndrome, reflecting the field's established view that brain iron insufficiency is part of the disease's own pathophysiology, not a downstream effect of any specific drug used to treat it. No pregabalin-specific iron or ferritin measurement study, pre- and post-treatment, was located.

Mechanism

None connecting pregabalin's own pharmacology to iron status. Pregabalin has no confirmed gut-absorption interference (actively checked and found absent elsewhere in this dossier), no renal iron-wasting pathway, and no hepatic iron-storage mechanism described anywhere in its label or pharmacology literature.

Counter-evidence held on record

The restless-legs-syndrome literature treats iron insufficiency as a pre-existing, causal contributor to the disease itself, for which iron repletion is its own independent therapy alongside, not because of, pregabalin. Do not present iron status in pregabalin-treated patients as caused by the drug. It reflects the underlying restless-legs-syndrome or other indication far more than any documented pregabalin pharmacology, exactly as with vitamin D and fibromyalgia above.

Trenkwalder C, Allen R, Högl B, et al. "Comorbidities, treatment, and pathophysiology in restless legs syndrome." — Lancet Neurol. 2018. PMID 30244828. Class-level review discussing pregabalin and iron repletion as separate treatment approaches for restless legs syndrome; cited only to document the restless-legs-iron confound, not as a pregabalin-iron pharmacokinetic study. Tier C for this specific drug-nutrient question.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Yellow — Low

See study details

A 2025 rat study directly measured gut microbiota composition with pregabalin as a treatment arm, rather than only reporting constipation as a symptom, but this review could not retrieve the full results to state which direction, or which taxa, changed.

Full detail, limits and 1 references

Limits on what this shows

Key negative / null findings: None located specific to microbiome composition. The FDA label's own gastrointestinal adverse-reaction data (constipation, dry mouth) is symptom-level reporting, not composition data, and is not used here as either support or refutation of a composition claim.
At-risk subgroups: None established in humans. The one located study is a rat neuropathic-pain model; no human pregabalin microbiome-composition study (16S rRNA sequencing or equivalent) was located.

Regulatory status

The FDA label documents constipation as a labeled gastrointestinal adverse reaction (a symptom report), not a microbiome-composition finding; the two are not the same category of evidence and must not be conflated.

Population evidence

Hong SW, Piao L, Cho EH, Seo EH, Kim SH. "Effect of Microglial Activity on Gut Microbiota in Rats with Neuropathic Pain." Int J Mol Sci. 2025;PMID 40507989. Confirmed via the PubMed listing snippet: the study "aimed to investigate the relationship between microglial activity and gut microbiota composition in a rat model of neuropathic pain, and to evaluate how pregabalin treatment may influence these interrelated parameters," with pregabalin as one of the treatment arms. This is a direct, drug-specific animal study that measured composition, not only symptoms. This review could not retrieve the full abstract or results (repeated source access failures during this session) to confirm the direction, magnitude, or specific taxa affected, and that gap is stated here rather than filled with an assumed direction.

Mechanism

Mechanism class G (microbiome disruption), plausible only: the study's own framing links microglial activity, a CNS process pregabalin is designed to modulate, to gut microbiota composition via the documented gut-brain axis, which is a real physiological pathway in general, but the direction and magnitude specific to pregabalin were not retrievable in this review.

Counter-evidence held on record

None located; this review's search access did not extend to a countervailing composition study, but the absence of a search result is not evidence of absence, so this is not presented as reassuring, only as unresolved. Do not present pregabalin-associated constipation as evidence of a microbiome shift; it is a labeled gastrointestinal symptom, not a composition finding. Do not state a direction of microbiome change that this review could not verify from the primary source.

Hong SW, Piao L, Cho EH, Seo EH, Kim SH. "Effect of Microglial Activity on Gut Microbiota in Rats with Neuropathic Pain." — Int J Mol Sci. 2025. PMID 40507989. Direct pregabalin-dosed rat study measuring gut microbiota composition. Full abstract with directional results could not be retrieved in this review; only the confirmed listing snippet describing the study's aim was available.Full abstract could not be retrieved after repeated attempts during this session (source rate-limiting). Direction and magnitude of any pregabalin-associated microbiota change are not cited as known; only the study's existence and stated aim are cited.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery/utilization

Orange — Moderate

See study details

Pregabalin's own carcinogenicity studies show a dose-dependent increase in malignant vascular liver tumors in mice, and a direct pregabalin-dosed toxicology study proposes hepatic hypoxia and reactive endothelial proliferation as the mechanism; this is a rodent tumor-biology finding of a kind the FDA label itself calls of unknown human significance, not a human anemia or oxygen-carrying-capacity finding.

Full detail, limits and 1 references

Limits on what this shows

Key negative / null findings: The FDA label's Hemic and Lymphatic adverse-reaction listing for pregabalin (thrombocytopenia, leukopenia) does not include anemia or any oxygen-carrying-capacity finding. No human study located in this review measured tissue oxygenation, hemoglobin oxygen saturation, or oxygen consumption in pregabalin-treated patients.
At-risk subgroups: None established in humans. The carcinogenicity finding is specific to two tested mouse strains under long-term, high-dose rodent study protocols; a species-specific mechanism (rodents are disproportionately prone to this class of vascular tumor finding under chronic high-dose dosing) is the leading explanation offered in the toxicology literature generally, though the label does not itself state this explicitly for pregabalin.

Regulatory status

FDA label, Carcinogenesis subsection: "A dose-dependent increase in the incidence of malignant vascular tumors (hemangiosarcomas) was observed in two strains of mice" given pregabalin in long-term studies. The label states directly: "The clinical significance of this finding is unknown. Clinical experience during LYRICA's premarketing development provides no direct means to assess its potential for inducing tumors in humans."

Population evidence

Criswell KA, et al. "Pregabalin induces hepatic hypoxia and increases endothelial cell proliferation in mice." Toxicol Sci. 2012;PMID 22539613. Direct pregabalin-dosed mouse study; title and PubMed listing confirm hepatic hypoxia and increased endothelial cell proliferation as findings. This review could not retrieve the full abstract (repeated 429 errors from the publisher/PubMed during this session) to confirm the specific dose, exposure duration, or quantitative magnitude, and that gap is flagged rather than filled with an invented figure.

Mechanism

Proposed, mouse-specific: chronic high-dose pregabalin exposure is associated with localized hepatic tissue hypoxia, which is proposed to drive a reactive angiogenic (endothelial-proliferative) response that, over long-term high-dose rodent carcinogenicity studies, associates with vascular tumor formation. This is not the drug's therapeutic mechanism of action (calcium-channel modulation) and is not proposed anywhere as a nutrient-pathway effect; it is a distinct, mouse-specific toxicological finding, catalogued here because it is a genuine tissue-oxygenation finding, not filed as a nutrient deficiency.

Counter-evidence held on record

The label explicitly disclaims a known human carcinogenic mechanism from this finding. No epidemiological signal for hepatic angiosarcoma, hypoxia, or any oxygen-delivery impairment has been reported in pregabalin's human safety database as reflected in the label's own Adverse Reactions sections. This is a rodent carcinogenicity-study mechanism, not a human finding, not an anemia finding, and not a nutrient deficiency. Never present it as evidence that pregabalin impairs oxygen delivery in people, and never pair it with an iron, B12, or oxygen-support supplement suggestion, which this finding does not support in any direction.

Criswell KA, Sulkowski ZL, Chen T, et al. "Pregabalin induces hepatic hypoxia and increases endothelial cell proliferation in mice." — Toxicol Sci. 2012. PMID 22539613. Direct pregabalin-dosed mouse toxicology study proposing the mechanism behind the FDA label's mouse hemangiosarcoma carcinogenicity finding. Full quantitative abstract (dose, duration) could not be retrieved in this review; the title and confirmed listing describe hepatic hypoxia and increased endothelial cell proliferation as findings.Full abstract could not be retrieved after repeated attempts during this session (429 errors). Dose and exposure duration are not cited as known; only the title-level finding is cited.

ATP production

Not graded — disclosed evidence gap

See study details

No Tier B mechanistic or Tier C class-extrapolation evidence connecting pregabalin specifically to cellular ATP production was located in this review, and no circulating consumer claim was found to rebut, so this category is printed as an open gap rather than forced into a color.

Full detail, limits and 1 references

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded · evidence gap

Limits on what this shows

Key negative / null findings: None located either way. This is a genuine absence of data, not a tested-and-negative finding like the mitochondrial chromaffin-cell study above.
At-risk subgroups: None can be stated; no population has been studied for this specific parameter with pregabalin.

Regulatory status

Not addressed anywhere in the FDA label. No mitochondrial-energetics or ATP-related finding of any kind appears in pregabalin's prescribing information.

Population evidence

None located that specifically measured cellular ATP levels, ATP synthesis rate, or mitochondrial oxygen-consumption rate with pregabalin dosing. A search for the underlying in vitro mitotoxicity screening paper referenced in the Mitochondrial Burden entry above (PMID 37239154) could not be independently verified for its specific endpoints in this review (repeated 429 errors from the source during this session), so it is not extended to support an ATP-specific claim here; it is referenced only, under the entry above, not counted twice.

Mechanism

None established or proposed anywhere in the literature located for this review. Pregabalin's mechanism of action is presynaptic calcium-channel modulation (the α2&delta subunit), which is a distinct pharmacological pathway from oxidative phosphorylation or ATP synthesis, and this dossier does not file that calcium-channel mechanism itself as an ATP-production finding.

Counter-evidence held on record

A direct pregabalin-dosed in vitro study (e.g. a Seahorse oxygen-consumption-rate assay or a luciferase-based cellular ATP assay) reporting ATP levels or synthesis rate, or a human study using a validated functional marker of mitochondrial energetics in pregabalin-treated patients, would let this category move to an actual grade in either direction.

Bin Dayel FF, Alfirevic A, Chadwick AE. "Developing In Vitro Models to Define the Role of Direct Mitochondrial Toxicity in Frequently Reported Drug-Induced Rhabdomyolysis." — Biomedicines. 2023. PMID 37239154. Located via PubMed search listing; whether pregabalin specifically was flagged as mitotoxic in this screen could not be independently verified in this review after repeated 429 errors opening the primary source, so this citation is used only to document the source's existence, not to support a specific claim.Full abstract could not be retrieved after repeated attempts during this session (429 errors). No statistic or specific finding from this source is cited as verified anywhere in this dossier.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

Folate
Where it comes from: Circulates as a class-wide "gabapentinoids lower folate" extension of gabapentin's own Linnebank association.
Why it fails: The same primary study that includes pregabalin explicitly places it in the vitamin-B12-associated group, not the folate-associated group (folate: carbamazepine, gabapentin, oxcarbazepine, phenytoin, primidone, valproate). Pregabalin's own cohort data contradicts a folate-specific claim.
Calcium / magnesium / antacid timing
Where it comes from: Assumed to transfer from gabapentin's confirmed antacid-bioavailability warning, since both drugs are marketed as "gabapentinoids."
Why it fails: Pregabalin's FDA label contains no aluminum-hydroxide or magnesium-hydroxide interaction language anywhere in sections 7 or 12.3, despite a specific, deliberate search. This appears to be a class-confusion error, not a documented pregabalin interaction.
Vitamin D "activation" / phosphate wasting
Where it comes from: Proposed by analogy to an α2&delta-calcium-channel-linked vitamin-D mechanism sometimes cited in gabapentin discussions.
Why it fails: No verifiable literature could be located tying gabapentinoid calcium-channel pharmacology to vitamin D activation or phosphate handling specifically, despite extensive targeted search. The real musculoskeletal literature on this class describes a direct calcium-channel-subunit effect on bone and muscle tissue instead, and pregabalin's own direct laboratory studies show no depletion signal, one shows an osteoanabolic direction.
"Pregabalin + B12 combination products prove pregabalin causes B12 loss"
Where it comes from: Commercial fixed-dose combination products, marketed in some countries, pairing pregabalin with methylcobalamin for diabetic or neuropathic pain.
Why it fails: These products treat B12 deficiency as a plausible independent contributor to neuropathic pain itself (confounding by indication), not as a correction for a pregabalin-induced deficiency. No trial in this literature attributes the B12 need to pregabalin's own pharmacology.
Bone fracture risk as proof of calcium / vitamin D deficiency
Where it comes from: Population-based fracture-risk studies in gabapentinoid users are sometimes read as proof of a mineral deficiency.
Why it fails: Fracture is a clinical outcome, not a measured nutrient level. No cited fracture study measured vitamin D, calcium, or phosphate status in the same patients, so it cannot support a nutrient-deficiency claim regardless of how real any fracture association may be at a class level.

What the research says is worth watching

General information from the medication label and the studies above. It is not personal medical advice, and any change belongs with your prescriber.

Labs
Vitamin B12, if clinically indicated
No routine screening is established by pregabalin's label. The single cohort signal is strongest in epilepsy patients on combination AED therapy; ordinary clinical judgment applies rather than a pregabalin-specific protocol.
Renal function
Creatinine clearance at baseline and with dose changes
Pregabalin requires dose reduction as renal function falls, and impaired kidneys independently disturb the phosphate, vitamin D, and PTH axis. Any mineral abnormality in a renally impaired patient on pregabalin should be worked up as a kidney-disease finding first, not as a drug-nutrient interaction.
Context
Indication, not drug, drives vitamin D and B12 baseline
Fibromyalgia, chronic neuropathic pain, and epilepsy each carry their own nutrient-status associations independent of pregabalin. Test and treat on clinical grounds; do not attribute a low result to pregabalin without first excluding the underlying condition.
Safety
Peripheral edema and weight gain are not nutrient signs
Both are labeled pregabalin adverse effects with their own mechanisms (fluid retention, appetite and metabolic changes). Never work these up as, or file them as, a nutrient deficiency.

All references used above

Pregabalin

Findings for this medication

What the research found

Vitamin B12

Food slows absorption rate

Vitamin D

The five body-system areas

⚡Mitochondrial Burden

Mitochondrial burden

💥Oxidative Stress

Oxidative stress

⚖️Copper and Iron Balance

Copper

Iron

🌿Gut Microbiome Risk

Gut microbiome risk

💨Oxygen and ATP Output

Oxygen delivery/utilization

ATP production

Claims checked and not supported

Folate

Calcium / magnesium / antacid timing

Vitamin D "activation" / phosphate wasting

"Pregabalin + B12 combination products prove pregabalin causes B12 loss"

Bone fracture risk as proof of calcium / vitamin D deficiency

What the research says is worth watching

Mitochondrial Burden

Oxidative Stress

Copper and Iron Balance

Gut Microbiome Risk

Oxygen and ATP Output